{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:06Z","timestamp":1792782546309,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Eastern Finland","id":[{"id":"https:\/\/ror.org\/00cyydd11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hodgkin lymphoma (HL) is a B-cell neoplasm with a cure rate of 90%. Previous data on late morbidity in patients with HL cover the era of older treatment modalities. This real-world study consisted of 2912 patients diagnosed with HL between 2000 and 2019 in Finland and aimed to clarify the incidence of late-onset cardiopulmonary morbidity compared to matched controls. Patient data were collected from four nationwide Finnish healthcare registries. We reported a higher occurrence of coronary artery disease in patients aged\u2009&lt;\u200950 years at diagnosis than in controls (RR 3.80 (2.16\u20136.74),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090001). Additionally, a higher incidence of both heart failure (RR 1.68 (1.28\u20132.21),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and valvular heart disease (RR 1.80 (1.17\u20132.78),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006) was detected in patients aged\u2009\u2265\u200950 years at diagnosis than in the controls. Remarkably, in the &lt;\u200950 years age group, the incidences of pneumonia (RR 4.89 (3.58\u20136.71),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and pulmonary embolism (RR 7.78 (2.75\u201321.95),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) were higher than those in the control group. In conclusion, with the current treatment modalities, late cardiopulmonary morbidity in long-term survivors remains a great challenge. A strategy for primary prevention and early detection of late toxicity remains crucial and a critical evaluation of current treatment practices is warranted.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07193-9","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:46:02Z","timestamp":1784727962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0894-6333","authenticated-orcid":false,"given":"Noora","family":"Hannuksela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"R\u00f6nk\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Anttalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"Ukkola-Vuoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iiro","family":"Toppila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Vikkula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sepp\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"Vuolukka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Kuitunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatu","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Partanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"1","key":"7193_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.15614","volume":"184","author":"H-W Wang","year":"2019","unstructured":"Wang H-W, Balakrishna JP, Pittaluga S et al (2019) Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol 184(1):45\u201359","journal-title":"Br J Haematol"},{"key":"7193_CR2","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1200\/JCO.20.02668","volume":"35","author":"AM Evens","year":"2020","unstructured":"Evens AM, Parsons SK (2020) Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality. J Clin Oncol 35:4131\u20134134","journal-title":"J Clin Oncol"},{"issue":"4","key":"7193_CR3","first-page":"419","volume":"29","author":"D Eichenauer","year":"2018","unstructured":"Eichenauer D, Aleman B, Andr\u00e9 M et al (2018) Hodgkin Lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(4):419\u2013429","journal-title":"Ann Oncol"},{"key":"7193_CR4","unstructured":"Cancer statistics [Internet]. Sy\u00f6p\u00e4rekisteri (2022) [cited 2023 July]. Available from: https:\/\/syoparekisteri.fi\/tilastot\/tautitilastot\/"},{"issue":"1","key":"7193_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-019-0799-1","volume":"12","author":"L Zhou","year":"2019","unstructured":"Zhou L, Deng Y, Li N et al (2019) Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J Hematol Oncol 12(1):107","journal-title":"J Hematol Oncol"},{"issue":"8","key":"7193_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/ajh.25856","volume":"95","author":"SM Ansell","year":"2020","unstructured":"Ansell SM, Hodgkin lymphoma (2020) A 2020 update on diagnosis, risk-stratification, and management. Am J Hematol 95(8):978\u2013989","journal-title":"Am J Hematol"},{"issue":"14","key":"7193_CR7","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1182\/bloodadvances.2022007363","volume":"6","author":"KL Chohan","year":"2022","unstructured":"Chohan KL, Young JR, Lester S et al (2022) A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. Blood Adv 6(14):4241\u20134250","journal-title":"Blood Adv"},{"issue":"1","key":"7193_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/jha2.1","volume":"1","author":"JR Gunther","year":"2020","unstructured":"Gunther JR, Pinnix CC, Glober GR, Christopherson KM, Fang P, Lee HJ, Ahmed S, Steiner RE, Nair R, Strati P, Neelapu SS, Nastoupil LJ, Dabaja BS (2020) Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes? EJHaem. 1(1):272\u2013276","journal-title":"EJHaem"},{"issue":"6","key":"7193_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","volume":"18","author":"R Hoppe","year":"2020","unstructured":"Hoppe R, Advani R, Ai W et al (2020) Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(6):755\u2013781","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"7193_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","volume":"53","author":"AK Ng","year":"2016","unstructured":"Ng AK, van Leeuwen FE (2016) Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance. Semin Hematol 53(3):209\u2013215","journal-title":"Semin Hematol"},{"issue":"1","key":"7193_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/asheducation-2011.1.323","volume":"2011","author":"DC Hodgson","year":"2011","unstructured":"Hodgson DC (2011) Late effects in the era of modern therapy for Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2011(1):323\u2013329","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"7193_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2141.2011.08713.x","volume":"154","author":"AK Ng","year":"2011","unstructured":"Ng AK (2011) Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 154:23\u201331","journal-title":"Br J Haematol"},{"issue":"11","key":"7193_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11883-017-0678-6","volume":"19","author":"AJ Kattoor","year":"2017","unstructured":"Kattoor AJ, Pothineni NVK, Palagiri D et al (2017) Oxidative Stress in Atherosclerosis. Curr Atheroscler Rep 19(11):42","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"7193_CR14","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","volume":"2","author":"MV Maraldo","year":"2015","unstructured":"Maraldo MV, Giusti F, Vogelius IR et al (2015) Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2(11):e492\u2013e502","journal-title":"Lancet Haematol"},{"issue":"6","key":"7193_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen FA, Schaapveld M, Janus CPM et al (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175(6):1007\u20131017","journal-title":"JAMA Intern Med"},{"issue":"2","key":"7193_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/10428194.2019.1663419","volume":"61","author":"K Taparra","year":"2020","unstructured":"Taparra K, Liu H, Polley M-Y et al (2020) Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma 61(2):298\u2013308","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"7193_CR17","first-page":"1281","volume":"66","author":"PG Tsoutsou","year":"2006","unstructured":"Tsoutsou PG, Koukourakis MI (2006) Radiation pneumonitis and fibrosis: Mechanisms underlying its pathogenesis and implications for future research. IJROBP 66(5):1281\u20131293","journal-title":"IJROBP"},{"issue":"1","key":"7193_CR18","first-page":"175","volume":"92","author":"P CC Pinnix","year":"2015","unstructured":"Pinnix P CC, Smith GL, Milgrom S et al (2015) Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiotherapy for Hodgkin and Non-Hodgkin Lymphoma. IJROBP 92(1):175\u2013182","journal-title":"IJROBP"},{"issue":"9","key":"7193_CR19","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/sj.bjc.6603999","volume":"97","author":"R Newton","year":"2007","unstructured":"Newton R, Crouch S, Ansell P et al (2007) Hodgkin\u2019s lymphoma and infection: findings from a UK case-control study. Br J Cancer 97(9):1310\u20131314","journal-title":"Br J Cancer"},{"key":"7193_CR20","doi-asserted-by":"publisher","first-page":"e019860","DOI":"10.1136\/bmjopen-2017-019860","volume":"7","author":"KK S\u00f8gaard","year":"2017","unstructured":"S\u00f8gaard KK, Farkas DK, S\u00f8rensen HT (2017) Pneumonia diagnosis in childhood and incidence of leukaemia, lymphoma and brain cancer: a Danish nationwide cohort study. BMJ Open 7:e019860","journal-title":"BMJ Open"},{"issue":"11","key":"7193_CR21","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1038\/bjc.2014.173","volume":"110","author":"LA Anderson","year":"2014","unstructured":"Anderson LA, Atman AA, McShane CM et al (2014) Common infection-related conditions and risk of lymphoid malignancies in older individuals. Br J Cancer 110(11):2796\u20132803","journal-title":"Br J Cancer"},{"issue":"6","key":"7193_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","volume":"73","author":"VT Devita","year":"1970","unstructured":"Devita VT, Serpick AA, Carbone PP (1970) Combination Chemotherapy in the Treatment of Advanced Hodgkin\u2019s Disease. Ann Intern Med 73(6):881\u2013895","journal-title":"Ann Intern Med"},{"issue":"1","key":"7193_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/cancers14010061","volume":"14","author":"S Oliva","year":"2021","unstructured":"Oliva S, Puzzovivo A, Gerardi C et al (2021) Late cardiological sequelae and long-term monitoring in classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a systematic review by the Fondazione Italiana Linfomi. Cancers (Basel) 14(1):61","journal-title":"Cancers (Basel)"},{"key":"7193_CR24","unstructured":"Cancer Research UK Average number of deaths per year and age-specific mortality rates per 100,000 persons population, UK, 2017\u20132019. Cancer statistics: Hodgkin lymphoma statistics [Internet]. 2022 [cited 2024 Jun 28]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/hodgkin-lymphoma\/mortality#heading-One"},{"issue":"12","key":"7193_CR25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ajh.24184","volume":"90","author":"I Glimelius","year":"2015","unstructured":"Glimelius I, Ekberg S, Jerkeman M et al (2015) Long -term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics. Am J Hematol 90(12):1128\u20131134","journal-title":"Am J Hematol"},{"issue":"6","key":"7193_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682","journal-title":"Am J Epidemiol"},{"issue":"2","key":"7193_CR27","first-page":"197","volume":"10","author":"M Tubiana","year":"1984","unstructured":"Tubiana M, Henry-Amar M, Hayat M et al (1984) The EORTC treatment of early stages of Hodgkin\u2019s disease: The role of radiotherapy. IJROBP 10(2):197\u2013210","journal-title":"IJROBP"},{"key":"7193_CR28","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1093\/annonc\/7.suppl_4.S115","volume":"7","author":"M Henry-Amar","year":"1996","unstructured":"Henry-Amar M, Joly F (1996) Late complications after Hodgkin\u2019s disease. Ann Oncol 7:S115\u2013S126","journal-title":"Ann Oncol"},{"key":"7193_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1200\/JCO.1987.5.1.27","volume":"5","author":"A Santoro","year":"1987","unstructured":"Santoro A, Bonadonna G, Valagussa P et al (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin\u2019s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27\u201337","journal-title":"J Clin Oncol"},{"key":"7193_CR30","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT et al (2010) Reduced Treatment Intensity in Patients with Early-Stage Hodgkin\u2019s Lymphoma. N Engl J Med 363:640\u2013652","journal-title":"N Engl J Med"},{"issue":"4","key":"7193_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00277-021-04460-9","volume":"100","author":"J Russell","year":"2021","unstructured":"Russell J, Collins A, Fowler A et al (2021) Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Ann Hematol 100(4):1049\u20131058","journal-title":"Ann Hematol"},{"issue":"16","key":"7193_CR32","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","volume":"270","author":"SL Hancock","year":"1993","unstructured":"Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease. JAMA 270(16):1949\u20131955","journal-title":"JAMA"},{"issue":"19","key":"7193_CR33","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"A Engert","year":"2003","unstructured":"Engert A, Schiller E, Josting P et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: Results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group. JCO 21(19):3601\u20133608","journal-title":"JCO"},{"issue":"3","key":"7193_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3324\/haematol.2009.015644","volume":"95","author":"C Herbst","year":"2010","unstructured":"Herbst C, Rehan FA, Brillant C et al (2010) Combined modality treatment improves tumor control and overall survival in patients with early-stage Hodgkin\u2019s lymphoma: a systematic review. Haematologica 95(3):494\u2013500","journal-title":"Haematologica"},{"issue":"1007","key":"7193_CR35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1259\/bjr\/22373346","volume":"84","author":"M Teoh","year":"2011","unstructured":"Teoh M, Clark CH, Wood K et al (2011) Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 84(1007):967\u2013996","journal-title":"Br J Radiol"},{"issue":"3","key":"7193_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jnci.2016.04.007","volume":"28","author":"C Higby","year":"2016","unstructured":"Higby C, Khafaga Y, Al-Shabanah M et al (2016) Volumetric-modulated arc therapy (VMAT) versus 3D-conformal radiotherapy in supra-diaphragmatic Hodgkin\u2019s Lymphoma with mediastinal involvement: A dosimetric comparison. J Egypt Natl Cancer Inst 28(3):163\u2013168","journal-title":"J Egypt Natl Cancer Inst"},{"issue":"4","key":"7193_CR37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/cancers16040690","volume":"16","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Patil D, Joshi K et al (2024) Dosimetric Impact of Voluntary Deep Inspiration Breath Hold (DIBH) in Mediastinal Hodgkin Lymphomas: A Comparative Evaluation of Three Different Intensity Modulated Radiotherapy (IMRT) Delivery Methods Using Voluntary DIBH and Free Breathing Techniques. Cancers (Basel) 16(4):690","journal-title":"Cancers (Basel)"},{"issue":"Suppl 7","key":"7193_CR38","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T, ESMO Guidelines Working Group et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23(Suppl 7):vii155\u2013vii66","journal-title":"Ann Oncol"},{"issue":"2","key":"7193_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","volume":"117","author":"SL Galper","year":"2011","unstructured":"Galper SL, Yu JB, Mauch PM et al (2011) Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 117(2):412\u2013418. https:\/\/doi.org\/10.1182\/blood-2010-06-291328","journal-title":"Blood"},{"key":"7193_CR40","doi-asserted-by":"crossref","unstructured":"Hannuksela N, Partanen A, Anttalainen A et al (2024) Survival of patients with classical Hodgkin lymphoma in Finland: a national population-based analysis. Blood Cancer J 14(1) :139","DOI":"10.1038\/s41408-024-01125-4"},{"issue":"1","key":"7193_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0167-8140(97)00125-4","volume":"46","author":"C Glanzmann","year":"1998","unstructured":"Glanzmann C, Kaufmann P, Jenni R et al (1998) Cardiac risk after mediastinal irradiation for Hodgkin\u2019s disease. Radiother Oncol 46(1):51\u201362","journal-title":"Radiother Oncol"},{"issue":"4","key":"7193_CR42","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.amjcard.2015.11.027","volume":"117","author":"JM Bijl","year":"2016","unstructured":"Bijl JM, Roos MM, van Leeuwen-Segarceanu EM et al (2016) Assessment of Valvular Disorders in Survivors of Hodgkin\u2019s Lymphoma Treated by Mediastinal Radiotherapy \u00b1 Chemotherapy. AJC 117(4):691\u2013696","journal-title":"AJC"},{"issue":"41","key":"7193_CR43","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 43(41):4229\u20134361","journal-title":"Eur Heart J"},{"issue":"2","key":"7193_CR44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","volume":"22","author":"P Borchmann","year":"2021","unstructured":"Borchmann P, Pl\u00fctschow A, Kobe C et al (2021) PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(2):223\u2013234","journal-title":"Lancet Oncol"},{"issue":"1","key":"7193_CR45","first-page":"169","volume":"92","author":"MC Aznar","year":"2015","unstructured":"Aznar MC, Maraldo MV, Schut DA et al (2015) Minimizing late effects for patients with mediastinal Hodgkin lymphoma: Deep inspiration breath-hold, IMRT, or both? IJROBP 92(1):169\u2013174","journal-title":"IJROBP"},{"key":"7193_CR46","first-page":"1","volume":"00","author":"JH Vandtved","year":"2024","unstructured":"Vandtved JH, \u00d8vlisen AK, Baech J et al (2024) Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study. Br J Haematol 00:1\u201310","journal-title":"Br J Haematol"},{"key":"7193_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00277-010-1032-z","volume":"90","author":"J Ngeow","year":"2011","unstructured":"Ngeow J, Tan IB, Kanesvaran R et al (2011) Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin\u2019s lymphoma. Ann Hematol 90:67\u201372","journal-title":"Ann Hematol"},{"issue":"3","key":"7193_CR48","first-page":"487","volume":"100","author":"CW Lanks","year":"2019","unstructured":"Lanks CW, Musani AI, Hsia DW (2019) Community-acquired Pneumonia and Hospital-acquired Pneumonia. Med Clin N 100(3):487\u2013501","journal-title":"Med Clin N"},{"issue":"11","key":"7193_CR49","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1080\/10428194.2017.1307980","volume":"58","author":"HL Sun","year":"2017","unstructured":"Sun HL, Atenafu EG, Tsang R, Kukreti V, Marras TK, Crump M, Kuruvilla J (2017) Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. Leuk Lymphoma 58(11):2607\u20132614","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"7193_CR50","first-page":"132","volume":"12","author":"P Pajunen","year":"2005","unstructured":"Pajunen P, Koukkunen H, Ketonen M et al (2005) The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 12(2):132\u2013137","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"7193_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2017.02.017","volume":"77","author":"MK Leinonen","year":"2017","unstructured":"Leinonen MK, Miettinen J, Heikkinen S et al (2017) Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer 77:31\u201339","journal-title":"Eur J Cancer"},{"key":"7193_CR52","unstructured":"Finnish Lymphoma Group, Finnish Society for Oncology Hodgkin lymphoma treatment recommendations [Internet]. 2024 [cited 2025 Mar 24]. Available from: https:\/\/onkologiayhdistys.fi\/app\/uploads\/2024\/03\/Klassisen-ja-ei-klassisen-Hodgkinin-lymfooman-hoitosuositus-2024.pdf"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07193-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07193-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07193-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:02:54Z","timestamp":1792429374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07193-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7193"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07193-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AP reports honoraria from Behring and Abbvie and has participated in Scientific Advisory Board meetings organised by Abbvie, Janssen Cilag, Novartis, Pfizer, Sanofi, and Takeda. AR reports personal fees for speaking at symposia and financial support for attending conferences from Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Daichii Sankyo, and Roche. No financial support was received for the study. TM was a contractor of Takeda Oy during the study period. LU-V, IT, JV and AA were employees of Medaffcon Oy. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"462"}}